All patients
Age < 65y (younger) Age > 65y Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), nivolumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 017, 2015 0.59 [0.44; 0.79]
CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 057, 2015 0.73 [0.59; 0.90]
CheckMate 078, 2019 0.68 [0.52; 0.89]
0.80 [0.64 ; 1.00 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 5 76% 2,322 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
CheckMate 078, 2019 0.75 [0.61; 0.93]
0.53 [0.22 ; 1.23 ] CheckMate 017, 2015, CheckMate 078, 2019 2 77% 776 moderate not evaluable PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
CheckMate 078, 2019 0.79 [0.64; 0.97]
0.69 [0.44 ; 1.07 ] CheckMate 017, 2015, CheckMate 078, 2019 2 46% 776 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 017, 2015 0.62 [0.47; 0.81]
CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 057, 2015 0.92 [0.77; 1.10]
CheckMate 078, 2019 0.77 [0.62; 0.95]
0.91 [0.73 ; 1.12 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 5 80% 2,322 moderate not evaluable objective responses (ORR)detailed results CheckMate 017, 2015 2.60 [1.26; 5.35]
CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
CheckMate 057, 2015 1.70 [1.11; 2.61]
CheckMate 078, 2019 4.40 [1.99; 9.74]
1.82 [0.86 ; 3.88 ] CheckMate 017, 2015, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 86% 1,781 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
CheckMate 078, 2019 4.80 [2.14; 10.77]
1.63 [0.19 ; 14.17 ] CheckMate 017, 2015, CheckMate 078, 2019 2 91% 776 moderate not evaluable AE (any grade)detailed results CheckMate 057, 2015 0.31 [0.20; 0.48]
0.31 [0.20 ; 0.48 ] CheckMate 057, 2015 1 0% 555 NA not evaluable AE (grade 3-4)detailed results CheckMate 057, 2015 0.42 [0.29; 0.59]
0.42 [0.29 ; 0.59 ] CheckMate 057, 2015 1 0% 555 NA not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
0.10 [0.03 ; 0.33 ] CheckMate 017, 2015 1 0% 260 NA not evaluable STRAE (any grade)detailed results CheckMate 017, 2015 0.23 [0.11; 0.51]
CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 057, 2015 0.32 [0.19; 0.55]
CheckMate 078, 2019 0.59 [0.34; 1.02]
0.47 [0.26 ; 0.86 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 78% 1,838 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 057, 2015 0.25 [0.14; 0.46]
CheckMate 078, 2019 0.34 [0.18; 0.66]
0.42 [0.20 ; 0.89 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 3 80% 1,578 moderate not evaluable TRAE (any grade)detailed results CheckMate 017, 2015 0.22 [0.12; 0.41]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 078, 2019 0.35 [0.22; 0.57]
0.26 [0.18 ; 0.37 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 3 24% 1,283 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.06 [0.03; 0.13]
CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 057, 2015 0.10 [0.06; 0.16]
CheckMate 078, 2019 0.15 [0.10; 0.24]
0.13 [0.08 ; 0.20 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 72% 1,838 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 078, 2019 0.61 [0.14; 2.77]
0.47 [0.12 ; 1.80 ] CheckMate 017, 2015, CheckMate 078, 2019 2 0% 753 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 017, 2015 0.28 [0.09; 0.89]
CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 078, 2019 0.66 [0.32; 1.37]
0.61 [0.40 ; 0.93 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 3 3% 1,283 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 078, 2019 0.80 [0.33; 1.95]
0.79 [0.37 ; 1.68 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 3 47% 1,283 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.10 ; 4.35 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.12 [0.01; 2.29]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 057, 2015 0.13 [0.02; 1.07]
CheckMate 078, 2019 0.15 [0.02; 1.47]
0.07 [0.02 ; 0.22 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.01; 1.76]
CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 057, 2015 0.15 [0.02; 1.28]
0.13 [0.03 ; 0.56 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.02 [0.12 ; 8.75 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,578 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.03 [0.08 ; 13.41 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.23 [0.01; 5.17]
0.52 [0.07 ; 4.10 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.06; 15.91]
CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 057, 2015 0.15 [0.01; 3.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.34 [0.08 ; 1.38 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 057, 2015 0.62 [0.10; 3.74]
CheckMate 078, 2019 0.93 [0.03; 27.74]
0.54 [0.20 ; 1.47 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.37 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 2 0% 1,085 moderate not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.09 [0.01; 0.73]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 057, 2015 0.21 [0.06; 0.74]
CheckMate 078, 2019 0.27 [0.06; 1.15]
0.20 [0.10 ; 0.41 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.03 [0.00; 0.58]
CheckMate 057, 2015 0.02 [0.00; 0.27]
0.02 [0.00 ; 0.17 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
CheckMate 078, 2019 0.93 [0.03; 27.74]
1.15 [0.37 ; 3.58 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.23 [0.01; 6.90]
0.42 [0.03 ; 5.48 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.75 [0.08 ; 7.25 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,578 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.03; 7.42]
0.81 [0.09 ; 6.95 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.03; 7.42]
1.60 [0.40 ; 6.42 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 3 10% 1,578 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.04 ; 6.06 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.19 [0.02; 1.66]
CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
CheckMate 057, 2015 0.02 [0.00; 0.32]
CheckMate 078, 2019 0.02 [0.00; 0.18]
0.05 [0.02 ; 0.16 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.02 [0.12 ; 8.75 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,578 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.09 [0.00; 1.69]
0.32 [0.04 ; 2.37 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 1.87 [0.06; 55.99]
1.42 [0.11 ; 18.57 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 057, 2015 0.93 [0.13; 6.67]
0.41 [0.11 ; 1.52 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.01 [0.00; 0.15]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 057, 2015 0.00 [0.00; 0.08]
CheckMate 078, 2019 0.03 [0.01; 0.15]
0.02 [0.01 ; 0.05 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.15 [0.01; 3.09]
0.24 [0.04 ; 1.54 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.47 [0.02; 13.95]
0.73 [0.09 ; 6.27 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 017, 2015 1.98 [0.07; 59.45]
CheckMate 057, 2015 2.82 [0.29; 27.28]
CheckMate 078, 2019 3.74 [0.20; 71.10]
2.83 [0.58 ; 13.89 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.58 [0.07 ; 5.02 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,578 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.59 [0.08 ; 4.55 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 2.79 [0.14; 56.11]
1.34 [0.31 ; 5.74 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019 4 0% 1,838 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.06 [0.08 ; 13.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
CheckMate 078, 2019 6.60 [0.37; 116.99]
8.91 [1.16 ; 68.41 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
CheckMate 078, 2019 2.79 [0.14; 56.11]
4.10 [0.71 ; 23.60 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.23 [0.01; 5.17]
0.33 [0.03 ; 3.23 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 2 0% 1,085 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
0.04 [0.01 ; 0.31 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.28 [0.04 ; 1.93 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015 3 0% 1,345 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results CheckMate 057, 2015 0.15 [0.01; 3.09]
0.15 [0.01 ; 3.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Alopecia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Anaemia AE (grade 3-4)detailed results CheckMate 057, 2015 0.38 [0.13; 1.09]
0.38 [0.13 ; 1.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Arthralgia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.13; 6.67]
0.93 [0.13 ; 6.67 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Asthenia AE (grade 3-4)detailed results CheckMate 057, 2015 0.84 [0.35; 2.02]
0.84 [0.35 ; 2.02 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Back pain AE (grade 3-4)detailed results CheckMate 057, 2015 2.36 [0.45; 12.26]
2.36 [0.45 ; 12.26 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Constipation AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.13; 6.67]
0.93 [0.13 ; 6.67 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Cough AE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
1.87 [0.06 ; 55.99 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Decreased appetite AE (grade 3-4)detailed results CheckMate 057, 2015 1.17 [0.31; 4.40]
1.17 [0.31 ; 4.40 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.19; 4.66]
0.93 [0.19 ; 4.66 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dizziness AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.06; 15.00]
0.93 [0.06 ; 15.00 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dry skin AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dysgeusia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CheckMate 057, 2015 1.32 [0.58; 3.03]
1.32 [0.58 ; 3.03 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Erythema AE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
0.47 [0.02 ; 13.95 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Fatigue AE (grade 3-4)detailed results CheckMate 057, 2015 0.45 [0.20; 1.02]
0.45 [0.20 ; 1.02 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results CheckMate 057, 2015 0.01 [0.00; 0.24]
0.01 [0.00 ; 0.24 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Headache AE (grade 3-4)detailed results CheckMate 057, 2015 3.75 [0.17; 83.63]
3.75 [0.17 ; 83.63 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Increase AST AE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 7.05 [0.86; 57.74]
7.05 [0.86 ; 57.74 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Increased ALT AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.06; 15.00]
0.93 [0.06 ; 15.00 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Leucopenia AE (grade 3-4)detailed results CheckMate 057, 2015 0.02 [0.00; 0.31]
0.02 [0.00 ; 0.31 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results CheckMate 057, 2015 0.18 [0.02; 1.58]
0.18 [0.02 ; 1.58 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Myalgia AE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
1.87 [0.06 ; 55.99 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Nausea AE (grade 3-4)detailed results CheckMate 057, 2015 2.36 [0.45; 12.26]
2.36 [0.45 ; 12.26 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Neutropenia AE (grade 3-4)detailed results Out of scale CheckMate 057, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Oropharyngeal pain AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-14 23:36 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 360,719,721,720
